Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Merck
Medtronic
Colorcon
Baxter

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Relacorilant

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Relacorilant?

Relacorilant is an investigational drug.

There have been 8 clinical trials for Relacorilant. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2018.

The most common disease conditions in clinical trials are Syndrome, Cushing Syndrome, and Carcinoma. The leading clinical trial sponsors are Corcept Therapeutics, University of Chicago, and National Cancer Institute (NCI).

There are eight US patents protecting this investigational drug and forty-eight international patents.

Recent Clinical Trials for Relacorilant
TitleSponsorPhase
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerCorcept TherapeuticsPhase 2
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate CancerCorcept TherapeuticsPhase 1
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate CancerNational Cancer Institute (NCI)Phase 1

See all Relacorilant clinical trials

Clinical Trial Summary for Relacorilant

Top disease conditions for Relacorilant
Top clinical trial sponsors for Relacorilant

See all Relacorilant clinical trials

US Patents for Relacorilant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Relacorilant   Start Trial Glucocorticoid receptor modulators to treat pancreatic cancer Corcept Therapeutics, Inc. (Menlo Park, CA)   Start Trial
Relacorilant   Start Trial Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome Corcept Therapeutics, Inc. (Menlo Park, CA)   Start Trial
Relacorilant   Start Trial Glucocorticoid receptor modulators to treat cervical cancer Corcept Therapeutics, Inc. (Menlo Park, CA)   Start Trial
Relacorilant   Start Trial Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators Corcept Therapeutics, Inc. (Menlo Park, CA)   Start Trial
Relacorilant   Start Trial Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators Corcept Therapeutics, Inc. (Menlo Park, CA)   Start Trial
Relacorilant   Start Trial Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators CORCEPT THERAPEUTICS, INC. (Menlo Park, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Relacorilant

Drugname Country Document Number Estimated Expiration Related US Patent
Relacorilant Australia 2017323636 2036-09-09   Start Trial
Relacorilant Brazil 112019004322 2036-09-09   Start Trial
Relacorilant Canada 3034114 2036-09-09   Start Trial
Relacorilant China 109689044 2036-09-09   Start Trial
Relacorilant European Patent Office 3509584 2036-09-09   Start Trial
Relacorilant Israel 265217 2036-09-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Medtronic
Dow
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.